A unifying trend across these entities is the migration of engineered cellular and bispecific antibody immunotherapies from oncology into severe autoimmune disease, using shared antigen targets and immunologic logic. In highly refractory myasthenia gravis, autologous CD19/BCMA dual-target CAR-T therapy (evaluated in the Ruan et al. trial) achieves sustained B-cell depletion, reduction of pathogenic autoantibodies, and systemic immune reprogramming toward a less inflammatory state—translating into marked clinical improvement and steroid discontinuation in patients who failed conventional immunosuppression. This represents a direct conceptual transplant of oncologic CAR-T architecture (BCMA/CD19 targeting originally validated in multiple myeloma and B-cell malignancies) into autoimmune neurology, positioning B-cell/plasma-cell lineage depletion as a mechanistic bridge between cancer immunotherapy and autoimmunity.
In parallel, the multiple myeloma and lymphoma literature shows a maturing ecosystem of FDA-approved bispecific antibodies (teclistamab and elranatamab targeting BCMA and FcRH5 respectively, talquetamab targeting GPRC5D) alongside CAR-T products (ciltacabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel), raising second-generation clinical questions around therapeutic sequencing, resistance mechanisms, and differential patient-reported outcome trajectories (e.g., cognitive function and social well-being differences between idecabtagene vicleucel and ciltacabtagene autoleucel). Institutions such as Memorial Sloan Kettering's Myeloma Service and JNCCN/ASCO Educational Book reviews are actively codifying sequencing guidance as the number of approved immunotherapies multiplies, while Blood Reviews-type analyses highlight persistent academic-versus-community disparities in novel therapy access and clinical trial enrollment for large B-cell lymphoma—an access-equity theme running alongside the science.
A second biomarker-driven thread concerns CLDN18.2-positive gastric cancer, where antibody-drug conjugates and bispecific antibodies are being developed against a target expressed independently of HER2 and PD-L1 status, defining a distinct therapeutic subpopulation and reflecting the broader field-wide strategy of layering antigen-specific biologics (ADCs, bispecifics, CAR-T) onto increasingly precise surface-marker stratification.
Collectively, these threads describe a macro trend: antigen-targeted cellular and bispecific immunotherapies, first optimized in hematologic malignancy, are being generalized (target reuse, mechanism reuse) into autoimmune disease and solid tumors, while the field simultaneously grapples with toxicity management (e.g., neurotoxicity syndromes), optimal sequencing, resistance biology, and equitable access as the therapeutic armamentarium rapidly expands.